Infertility Pharma Business Opportunity in India
Among the Indian population, 1 in 7 women is facing difficulty conceiving with known or unknown causes. Women prefer less burdensome methods before opting for intensive treatments like IUI or IVF. This is giving rise to digital Pharmacies.
This would turn out to be a great infertility Pharma Business opportunity for companies to enter the market and diversify their portfolio in the infertility treatment range. This could include tablets, capsules and injection drugs.
Companies could consider Adorshea a leading Gynaecology Pharma company in India, dealing with infertility problems by providing medication treatments in the form of Capsules, tablets, and Injectable formulations.
Infertility in India: Trends & Major Causes
According to the ICMR (Indian Council of Medical Research) National Survey on Infertility Prevalence, the number of couples experiencing Infertility problems is approx 27-29 million, with nearly 10-20% of the cases with unexplained causes.
The Major causes of Infertility are as follows:
Endometriosis: Endometriosis affects approx 41-43 million women population in India. Women are preferring non-surgical treatments for endometriosis, and those are most likely medications.
Ovulation Disorders: Due to Hormonal Imbalances, Women develop problems like PCOS (polycystic ovary syndrome, Thyroid issues and face difficulty in maintaining a healthy weight. They either end up as underweight or overweight.
Chronic Medical Conditions: High Blood Pressure, Diabetes, Kidney diseases, anemia etc lead to infertility in a few women.
Infertility Reported Among the Following States:
North India: Uttar Pradesh and Rajasthan show a higher infertility burden, while Punjab and Haryana fall into the moderate-burden category.
East India: Bihar is categorized as a higher-burden state, while West Bengal falls under the lower-burden category.
West India: Madhya Pradesh is categorized as having a higher infertility burden, while Gujarat and Maharashtra fall into the moderate-burden category.
South India: Kerala, Tamil Nadu and Karnataka are categorized under the lower-burden category.
Infertility Pharma Business Scope in India 2026
According to the Towards-Health report about Infertility Treatment Market trends, global infertility treatment industry is valued at approx USD 9.7 - 9.9 billion in 2026.
This calls for the need for businesses to diversify their Infertility-treatment Portfolio:
Pre-fertility Medicines: Pre-Fertility medicines aid women who are facing failure while conceiving naturally. The primary function of Pro-Fertility Medication is to assist with female infertility caused due to factors including ovulatory Dysfunctions, Low egg count, poor ovarian response etc.
Tablets and Capsules: Women prefer less burdensome treatments for infertility and oral medication is one of the best options available to them.
Injectable Fertility Medicines: According to Cohorent Market Insights, Indian Infertility Gonadotropins market is valued at USD 273 Million. FSH (Follicle-stimulating hormone) holds a significant market share, leading to growth in Injectable formulations.
ART Treatments: Assisted Reproductive Technology Treatments often take into account the use of medication alongside treatments.
Entering the Infertility Pharma Market: Key Factors to Consider
The growing Infertility Pharma Market is a great opportunity for Fertility & IVF Specialists, IVF & Fertility Clinics, Pharma Distributors, and Retail Pharmacies/Chemists for entry.
The following factors are important while considering the Infertility Pharma Business Opportunity in India:
Selection of Product Portfolio: As per the growing demand of medication treatment for Infertility, The company must consider diversifying their treatment portfolio with Tablets, Capsules and Injections to provide their end users with wide range of options.
Analysis of Infertility Pharma Market: Infertility Pharma is experiencing a growth in ART Treatments and infertility treatment medications. With AI, the Infertility Pharma Industry is moving towards hyper-personalisation of dosage.
Adherence to Regulations: Companies must adhere to all the regulations and quality standards of the Infertility Pharma Industry.
Development of Medical Professionals and Distribution Network: Having a network of medical professionals specialised in gynaecology and infertility gives a company an advantage over their competitors.
Choosing the best Pharma Partner: While selecting a Partner, the company’s professional experience and specialisation must align with your goals. Adorshea a leading Infertility Pharma company, is the best choice in this regard.
Why Choose Adorshea as Your Infertility Pharma Partner
Adorshea is an ISO certified firm and a leading gynae company in India in compliance with WHO-GMP Guidelines, specialising in women's healthcare.
Adorshea has professional experience of 5+ Years in gynecology, female healthcare, and infertility treatments.
For more than 5 years, Adorshea is offering the Infertility Pharma Products Ranges, Medications including
Capsules: Coral Calcium 750mg + Vitamin D3 500IU Capsules
Fenticonazole 600mg Capsules
Tablets: Calcium Citrate Malate, Vitamin D3 and Folic Acid Tablets
Isoxsuprine Hydrochloride 10mg Tablets
Injections: Aqua Progesterone 25mg Injection
Drotaverine Injection (2ml)
Conclusion:
Infertility in India is posing a serious challenge and the infertility pharma market is ready to take charge and provide treatments for infertility issues. But to tap the market in the right way one must be cautious with the selection of their infertility pharma business partner.
Adorshea with its 5+ years of professional experience in the Infertility Pharma Business, equips advanced technology like AI for precise formulation of their Pharma Products.
Comments
Post a Comment